Inventing the COVID vax pill: a matter of convenience and durability

The Latest

• 

  As pharma M&A ramps up, U.S. execs are bullish on more deals

  What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

  Biotech

• 

  4 ways to nail the launch of your cell therapy

  A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

  Biotech

• 

  Podcast

  Woman of the Week: COTA’s Miruna Sasu

  Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.

  Leadership

• 

  Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

  With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

  Biotech

• 

  Q&A

  How real world evidence is impacting rare disease drug development

  https://www.gettyimages.com/detail/photo/woman-at-home-using-cell-phone-and-checking-ehr-royalty-free-image/1249041723?adppopup=true

  Biotech

• 

  Are Big Pharma CEOs earning their pay?

  While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

  Biotech

• 

  The ‘alarming’ spread of Monkeypox — by the numbers

  With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

  Manufacturing

• 

  Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

  Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

  Patient

• 

  Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

  How these latest executive personnel changes are impacting the industry. 

  Biotech

• 

  Podcast

  Woman of the Week: Alloy Therapeutics’ Heather Schwoebel

  The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

  Biotech

• 

  Taking probiotics where they’ve never gone before

  How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

  Biotech

• 

  ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

  EverythingALS aims to speed drug development through improved diagnostics.

  Pharma

• 

  Q&A

  A glimpse inside Bristol Myers Squibb’s integration with Celgene

  Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

  Biotech

• 

  Q&A

  How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

  WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

  Biotech

• 

  Q&A

  Personalized data could bring PhysIQ to the forefront of clinical trial evolution

  The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

  Pharma

• 

  What’s next for Biogen? Here’s what executives are saying

  A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

  Biotech

• 

  Q&A

  Lupus discovery lends clues to the fight against long COVID

  So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

  Patient

• 

  Podcast

  Woman of the Week: Applied BioMath's Katie Williams

  The 2022 president of Women in Bio is equal parts math and gender parity evangelist. 

  Leadership

• 

  Democrats think they've found a balance between drug innovation and pricing negotiation

  A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

  Biotech

• 

  The earlier the better: New consortium leverages infant screening to accelerate treatment

  Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

  Biotech

• 

  A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

  The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

  Biotech

• 

  Q&A

  Behind Pfizer's new quest to target a 'transformation' in pharma

  A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

  Biotech

• 

  With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

  Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

  Pharma

• 

  Moderna's next vax target? A little-known cause of birth defects

  How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

  Biotech

• 

  By the numbers: The rising danger of superbugs

  A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

  Biotech